Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biotechnology
Takeda, Arrowhead enter $1 billion agreement to develop RNAi treatment
by Megha Satyanarayana
October 17, 2020
| A version of this story appeared in
Volume 98, Issue 40
Takeda Pharmaceutical and Arrowhead Pharmaceuticals will codevelop ARO-AAT, an Arrowhead RNA interference therapy for alpha-1 antitrypsin-associated liver disease. Arrowhead will receive $300 million up front, with subsequent payments totaling up to $740 million. Takeda will receive an exclusive license to commercialize the treatment outside the US, and the companies will develop it together in the US. There are no approved therapies for the disease, and it often leads to liver transplants.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter